Physician profile
William A Mitchell
NPI 1407309628
$3,717.76
in general payments reported to CMS, 2019-2025
9 companies · $593 in 2025
The $593 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $160 · 2021: $412 · 2022: $724 · 2023: $910 · 2024: $797 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,949.93 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $478.73 | 2019-2021 | |
| Alcon Vision LLC | $303.43 | 2019-2025 | Total30 |
| Coopervision INC. | $246.66 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Optos, INC. | $223.34 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $188.03 | 2022-2024 | Acuvue |
| Mallinckrodt Hospital Products INC. | $154.29 | 2023-2025 | Acthar |
| Glaukos Corporation | $151.34 | 2021-2025 | Photrexa Viscous and Photrexa |
| Heidelberg Engineering, INC. | $22.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.